Through a comprehensive analysis of the BC, CC, and DC parameters using the CytoNCA plug-in (Fig. 3), AKT1, EGFR, and SIRT1 were determined to be the main targets for FMN to treat SP, which is consistent with the aforementioned analysis. The gene discussed is EGFR; the disease is breast cancer.